5-Chloropyrazinamide (5-Cl-PZA) is an inhibitor of mycobacterial fatty acid synthase I with a broad spectrum of antimycobacterial activity in vitro. Some N-phenylpyrazine-2-carboxamides with different substituents on both the pyrazine and phenyl core possess significant in vitro activity against Mycobacterium tuberculosis. To test the activity of structures combining both the 5-Cl-PZA and anilide motifs a series of thirty 5-chloro-N-phenylpyrazine-2-carboxamides with various substituents R on the phenyl ring were synthesized and screened against M. tuberculosis H37Rv, M. kansasii and two strains of M. avium. Most of the compounds exerted activity against M. tuberculosis H37Rv in the range of MIC = 1.56-6.25 µg/mL and only three derivatives were inactive. The phenyl part of the molecule tolerated many different substituents while maintaining the activity. In vitro cytotoxicity was decreased in compounds with hydroxyl substituents, preferably combined with other hydrophilic substituents. 5-Chloro-N-(5-chloro-2-hydroxyphenyl)pyrazine-2-carboxamide (21) inhibited all of the tested strains (MIC = 1.56 µg/mL for M. tuberculosis; 12.5 µg/mL for other strains). 4-(5-Chloropyrazine-2-carboxamido)-2-hydroxybenzoic acid (30) preserved good activity (MIC = 3.13 µg/mL M. tuberculosis) and was rated as non-toxic in two in vitro models (Chinese hamster ovary and renal cell adenocarcinoma cell lines; SI = 47 and 35, respectively).

Faculty of Pharmacy in Hradec Králové Charles University Prague Heyrovského 1203 Hradec Králové 500 05 Czech Republic

See more in PubMed

World Health Organization . Global Tuberculosis Report 2013. WHO; Geneva, Switzerland: 2013. pp. 8–21. (WHO/HTM/TB/2013.11).

Cynamon M.H., Speirs R.J., Welch J.T. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother. 1998;42:462–463. PubMed PMC

Zimhony O., Cox J.S., Welch J.T., Vilcheze C., Jacobs W.R. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 2000;6:1043–1047. doi: 10.1038/79558. PubMed DOI

Boshoff H.I., Mizrahi V., Barry C.E. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol. 2002;184:2167–2172. doi: 10.1128/JB.184.8.2167-2172.2002. PubMed DOI PMC

Ngo S.C., Zimhony O., Chung W.J., Sayahi H., Jacobs W.R., Welch J.T. Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob. Agents Chemother. 2007;51:2430–2435. doi: 10.1128/AAC.01458-06. PubMed DOI PMC

Sayahi H., Pugliese K.M., Zimhony O., Jacobs W.R., Shekhtman A., Welch J.T. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I. Chem. Biodivers. 2012;9:2582–2596. doi: 10.1002/cbdv.201200291. PubMed DOI

Ahmad Z., Tyagi S., Minkowski A., Almeida D., Nuermberger E.L., Peck K.M., Welch J.T., Baughn A.S., Jacobs W.R., Grosset J.H. Activity of 5-chloropyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian J. Med. Res. 2012;135:808–814. PubMed PMC

Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: A review. Int. J. Tuberc. Lung Dis. 2003;7:6–21. PubMed

Dolezal M., Kesetovic D., Zitko J. Antimycobacterial evaluation of pyrazinoic acid reversible derivatives. Curr. Pharm. Des. 2011;17:3506–3514. doi: 10.2174/138161211798194477. PubMed DOI

Dolezal M., Zitko J., Jampilek J. Pyrazinecarboxylic Acid Derivatives with Antimycobacterial Activity. In: Cardona P.-J., editor. Understanding Tuberculosis—New Approaches to Fighting Against Drug Resistance. InTech; Rijeka, Croatia: 2012.

Servusova B., Vobickova J., Paterova P., Kubicek V., Kunes J., Dolezal M., Zitko J. Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides. Bioorg. Med. Chem. Lett. 2013;23:3589–3591. doi: 10.1016/j.bmcl.2013.04.021. PubMed DOI

Wardell S., de Souza M.V.N., Vasconcelos T.R.A., Ferreira M.D.L., Wardell J.L., Low J.N., Glidewell C. Patterns of hydrogen bonding in mono- and disubstituted N-arylpyrazinecarboxamides. Acta Crystallogr. Sect. B Struct. Sci. 2008;64:84–100. doi: 10.1107/S0108768107051804. PubMed DOI

Zitko J., Paterova P., Kubicek V., Mandikova J., Trejtnar F., Kunes J., Dolezal M. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution. Bioorg. Med. Chem. Lett. 2013;23:476–479. doi: 10.1016/j.bmcl.2012.11.052. PubMed DOI

Tostmann A., Boeree M.J., Peters W.H.M., Roelofs H.M.J., Aarnoutse R.E., van der Ven A., Dekhuijzen P.N.R. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int. J. Antimicrob. Agents. 2008;31:577–580. doi: 10.1016/j.ijantimicag.2008.01.022. PubMed DOI

Bispo M.D.F., Goncalves R.S.B., Lima C.H.D., Cardoso L.N.D., Lourenco M.C.S., de Souza M.V.N. Synthesis and Antitubercular Evaluation of N-Arylpyrazine and N,N’-Alkyl-diylpyrazine-2-carboxamide Derivatives. J. Heterocycl. Chem. 2012;49:1317–1322. doi: 10.1002/jhet.921. DOI

Servusova B., Eibinova D., Dolezal M., Kubicek V., Paterova P., Pesko M., Kral’ova K. Substituted N-Benzylpyrazine-2-carboxamides: Synthesis and Biological Evaluation. Molecules. 2012;17:13183–13198. doi: 10.3390/molecules171113183. PubMed DOI PMC

Tostmann A., Boeree M.J., Aarnoutse R.E., de Lange W.C.M., van der Ven A., Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J. Gastroenterol. Hepatol. 2008;23:192–202. doi: 10.1111/j.1440-1746.2007.05207.x. PubMed DOI

Singh M., Sasi P., Rai G., Gupta V.H., Amarapurkar D., Wangikar P.P. Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line. Med. Chem. Res. 2011;20:1611–1615. doi: 10.1007/s00044-010-9405-3. DOI

Singh M., Sasi P., Gupta V.H., Rai G., Amarapurkar D.N., Wangikar P.P. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model. Hum. Exp. Toxicol. 2012;31:788–797. doi: 10.1177/0960327111433901. PubMed DOI

Owen T.C. Tetrazolium Compounds for Cell Viability Assays. 5,185,450. U.S. Patent. 1993 Feb 9;

Jones R.N., Barry A.L. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. J. Clin. Microbiol. 1987;25:1920–1925. PubMed PMC

National Committee for Clinical Laboratory Standards . Method for Antifungal Disc Diffusion Susceptibility Testing of Yeasts: Approved Guideline M44-A. NCCLS; Wayne, PA, USA: 2004.

Antimicrobial and Antiproliferative Properties of 2-Phenyl-N-(Pyridin-2-yl)acetamides

Synthesis, Biological Evaluation, and In Silico Modeling of N-Substituted Quinoxaline-2-Carboxamides

5-Alkylamino-N-phenylpyrazine-2-carboxamides: Design, Preparation, and Antimycobacterial Evaluation

Substituted N-(Pyrazin-2-yl)benzenesulfonamides; Synthesis, Anti-Infective Evaluation, Cytotoxicity, and In Silico Studies

Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents

Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold

Ureidopyrazine Derivatives: Synthesis and Biological Evaluation as Anti-Infectives and Abiotic Elicitors

Synthesis of Novel Pyrazinamide Derivatives Based on 3-Chloropyrazine-2-carboxamide and Their Antimicrobial Evaluation

Synthesis and Antifungal Screening of 2-{[1-(5-Alkyl/arylalkylpyrazin-2-yl)ethylidene]hydrazono}-1,3-thiazolidin-4-ones

Synthesis and Biological Evaluation of N-Alkyl-3-(alkylamino)-pyrazine-2-carboxamides